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ABSTRACT: Dimeric/oligomeric states of G-protein coupled receptors have been diﬃcult to target. We report here bivalent
ligands consisting of two identical oxytocin-mimetics that induce a three order magnitude boost in G-protein signaling of
oxytocin receptors (OTRs) in vitro and a 100- and 40-fold gain in potency in vivo in the social behavior of mice and zebraﬁsh.
Through receptor mutagenesis and interference experiments with synthetic peptides mimicking transmembrane helices (TMH),
we show that such superpotent behavior follows from the binding of the bivalent ligands to dimeric receptors based on a TMH1-
TMH2 interface. Moreover, in this arrangement, only the analogues with a well-deﬁned spacer length (∼25 Å) precisely ﬁt inside
a channel-like passage between the two protomers of the dimer. The newly discovered oxytocin bivalent ligands represent a
powerful tool for targeting dimeric OTR in neurodevelopmental and psychiatric disorders and, in general, provide a framework
to untangle speciﬁc arrangements of G-protein coupled receptor dimers.
■ INTRODUCTION
G-protein coupled receptors (GPCRs), the largest eukaryotic
family of transmembrane proteins involved in cellular signal
transduction, have been shown to associate to form dimers
and/or higher order oligomers.1,2 Despite their promise as new
druggable targets, the molecular details of these complexes have
been elusive. Elucidating the number and arrangement of
protomers in homo- and hetero-oligomers, the cellular
distribution of these diﬀerent conformations and, most
importantly, their functional relevance in normal and
pathological conditions, still represents an extraordinary
challenge.3 Synthetic analogues speciﬁcally targeting GPCR
homomers and heteromers not only constitute a promising new
class of therapeutics but also represent powerful tools to
contribute to the enlightenment of how these complexes
function.
One strategy to pharmacologically target GPCR dimers is to
develop bivalent ligands, single chemical entities composed of
two covalently tethered pharmacophores. Such an approach
seeks to tether two pharmacophores with a spacer that enables
the ligands to bind simultaneously into the two protomers of a
dimeric receptor target.4−6 There are two general types of
bivalent ligands: heterobivalent, where the two pharmaco-
phores are diﬀerent, and homobivalent, where the two
pharmacophores are identical. So far, research has primarily
focused on the design of heterobivalent ligands to target
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orthosteric and allosteric binding sites within the same
receptor7 or in heteromeric receptor complexes. Heterobivalent
targeting of heteromeric receptors have been extensively
pursued by Portoghese and co-workers8 who reported the
most successful heterobivalent ligands developed to date and
which usually include at least one antagonist molecule.9,10
Homobivalent analogues have also been developed and
investigated. However, in the majority of cases, homobivalent
agonist ligands designed to probe dimeric receptors were found
to lose activity and became either partial agonists11−13 or, in
some cases, antagonists.14,15 Scattered reports of homobivalent
ligands with increased in vitro and/or in vivo eﬃcacy or potency
revealed very short linkers,16 more compatible with their
binding to diﬀerent sites within a single protomer7 than to the
two orthosteric sites of a dimeric receptor. A recent paper
reported homobivalent ligands for the melanocortin receptor
that display increased binding aﬃnity by 14- to 25-fold, slight
increased cyclic adenosine 3′,5′-monophosphate (cAMP)
signaling potency by 3- to 5-fold compared to their monovalent
counterparts; in vivo, these ligands signiﬁcantly decrease feeding
but at a dose that was similar to monovalent.17
In this work, we pharmacologically targeted dimeric
conformations of the human oxytocin receptor (OTR), a
prototypic class A GPCR that has been shown to form homo-
and heterodimers in vitro and in vivo.18 OTR homodimers and
OTR heterodimers with the highly related vasopressin V1a and
V1b receptors have been demonstrated in HEK 293 cells,19 and
evidence for in vivo OTR heterodimerization with the
dopamine D2 receptors20 and adrenergic β2 receptors21,22
has also been reported.
The oxytocin (OT) system is a key regulator of all the
aspects of social behavior,23 and in humans, OT facilitates the
processing of social information, improves cognitive empathic
abilities, and increases interpersonal trust.24 On the basis of
these premises, OT administration has been proposed and used
as a treatment of social deﬁcits in autistic25,26 and schizophrenic
patients,27 representing a domain of great expectations and
relevance.28 However, the short life of the endogenous peptide
and its limited selectivity urges for the development of new
potent oxytocin-mimetics for translational studies in vitro and in
vivo.29 To contribute toward addressing these issues, we
synthesized and characterized a series of homobivalent OT
analogues designed to speciﬁcally activate dimeric forms of the
human OTR. We tested these compounds for their capability to
bind and activate OTR homodimers and predicted, by
molecular modeling, their potential binding modes at a dimeric
OTR constellation. The suggested OTR dimer formation was
validated by mutagenesis studies and single transmembrane
interference assays in combination with G-protein activation.
Finally, we used mouse and zebraﬁsh animal models to study
highly potent bivalent agonistic OTR ligands in vivo.
■ RESULTS
Design Strategy and Synthesis of Homobivalent
dOTK Ligands. OT (1) is a nonapeptide neurohormone
characterized by a disulﬁde bond between the two cysteine
residues at positions 1 and 6 and a short C-terminal tripeptide
(Figure 1). Prior work demonstrated that deamination of
cysteine at position 1 and substitution of the leucine residue at
position 8 with other amino acids did not aﬀect the
Figure 1. Chemical structure of monovalent and bivalent analogues Schematic representation of OT (1), dOTK (2), dOTK-C8 (3), and bivalent
ligands (4a−e). OT (1) is a cyclic nonapeptide containing one internal disulﬁde bond between its Cys(1) and Cys(6) residues, and a tripeptide Pro
(7)-Leu (8)-Gly-NH2 (9) tail. The OT-modiﬁed peptide dOTK (2) has a deaminated N-terminus, and the Leu residue at position 8 was replaced
with a Lys residue (modiﬁcations are marked in pink). The dOTK molecule fused to the C8 spacer, dOTK-C8 (3), was used as the control. Two
dOTK molecules were covalently tethered with aliphatic spacers of diﬀerent lengths to generate ﬁve homobivalent ligands indicated as dOTK2−Cx
(4a−e), with X being the number of carbon atoms between the two lysine groups (including the carbonyl groups of the amide bonds that connect
the lysine residues with the spacer). Bivalent ligands with spacers of 8 and 10 atoms (C8 (4b) and C10 (4c)) are marked in magenta.
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pharmacological properties of the peptide toward the OTR.30
In particular, OT deaminated at position 1 and bearing a lysine
at position 8 and indicated here as dOTK (2) (Figure 1) could
be conjugated to the bulky group DOTA (1,4,7,10
tetraazacyclododecane-1,4,7,10-tetraacetic acid) without show-
ing any signiﬁcant drop in the aﬃnity for the OTR.30 On the
basis of these observations, we used the lysine side chain at
position 8 of dOTK as the conjugation site to generate a series
of diﬀerently sized bivalent dOTK ligands (4a−e), joined by
alkane spacers of diﬀerent lengths, from C6 to C14 atoms
(Figure 1). Alkane spacers were chosen on the basis of their
previous successful use in bivalent ligand design;8 moreover,
alkane spacers are ﬂexible and dynamic, their reaction
conditions fairly well established and with high yields, and are
commercially available in a whole range of lengths. The
chemical structure and nomenclature of these compounds are
schematically reported in Figure 1 and their synthesis in
Supporting Information, Experimental Section.
Mono- and Biphasic Activation of OTR by Monovalent
and Bivalent dOTK Ligands. The capability of OTR to form
homodimers was conﬁrmed via a bioluminescence resonance
energy transfer (BRET)31 saturation assay (Figure 2A). In this
experiment, HEK293 cells are cotransfected with a ﬁxed DNA
amount of OTR fused to the Renilla reniformis Luciferase (Rluc,
the BRET energy donor) and increasing DNA amounts of
OTR fused to the blue-shifted variant of Aequorea Victoria
green ﬂuorescent protein GFP2 (the BRET energy acceptor);
this allows for the formation of OTR-Rluc/OTR-GFP2 dimeric
complexes in a dose-dependent manner, which, by conse-
quence, leads to a dose-dependent increase in the BRET signal,
up to a point (a saturation plateau) where all OTR-Rluc
receptors are complexes with OTR-GFP2 receptors. As a
control to rule out the possibility that the observed BRET-
signal is not a consequence of stochastic collision events due to
receptor overexpression, the distantly related CD4 receptor
fused to GFP2 (CD4-GFP2) was coexpressed with OTR-Rluc.
As shown in Figure 2B, the OTR-Rluc and CD4-GFP2 pair
failed to produce a hyperbolic curve, whereas a robust and
saturable BRET signal (BRETmax 0.38 ± 0.04) was obtained for
Figure 2. BRET measurement of basal OTR homodimerization and OTR/Gq activation by monovalent and bivalent analogues. (A) Sketch of the
receptor constructs used in the BRET saturation assay to study dimerization. OTR fused to the BRET energy donor Renilla Luciferase (OTR-Rluc);
OTR fused to the BRET energy acceptor GFP2 (OTR-GFP2) and the CD4 receptor fused to the energy acceptor GFP2 (CD4-GFP2). (B) For OTR
homodimer formation, cells were transfected with ﬁxed amounts of DNA encoding for OTR-Rluc and increasing amounts of DNA encoding for
OTR-GFP2 or, for the negative control, CD4- GFP2. Data are expressed as the mean ± SEM and derived from an individual saturation curve
performed in triplicate, representative of at least three independent experiments. (C) Sketch of the Gq BRET activation assay. Energy transfer is
measured between Rluc (the energy donor) and GFP10 (the energy acceptor), introduced into the α helical domain of the Gαq subunit and the N-
terminal domain of Gγ2 (GFP
10-Gγ2), respectively. Ligand-induced OTR-Gq activation leads to a conformational rearrangement of the
heterotrimeric G protein complex, which promotes GDP release, and that corresponds to a decrease in the BRET energy transfer. BRET was
measured in HEK293 living cells coexpressing Gαq-RLuc8, GFP
10- Gγ2, Gβ1, and OTR. Cells were left untreated or stimulated with increasing
concentrations of (D) the monovalent agonists OT (1), dOTK (2), and dOTK fused to the C8 spacer (dOTK-C8) (3) or (E) the indicated bivalent
agonists (4a−e). Data were calculated as the diﬀerence in the BRET signal measured in the presence and absence of the agonist and are represented
as means ± SEM of at least three independent experiments. The background of graphs reporting biphasic responses is colored in light-orange.
Bivalent dOTK2−C8 (4b) and dOTK2−C10 (4c) activation curves are in magenta.
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OTR, a result consistent with the formation of OTR-Rluc/
OTR-GFP2 dimers.
To functionally evaluate monovalent and bivalent ligands, we
employed a BRET-based biosensor that measures the ligand
induced G protein activation (Figure 2C). In this biosensor, the
BRET energy donor Rluc is inserted within the Gα subunit
amino acid sequence, and the acceptor, a variant of the green
ﬂuorescent protein (GFP10), is N-terminally fused to the Gγ2
subunit (GFP10-Gγ2) .
31−33 Ligand-induced OTR-Gq activation
leads to GDP release coupled to a conformational rearrange-
ment of the heterotrimeric G protein complex and, by
consequence, to a decrease in the BRET ratio. Using this
assay, we previously demonstrated that OT (1) promotes OTR
coupling to several G-protein isoforms in a concentration-
dependent manner, allowing the identiﬁcation of Gq as being
engaged at a lower peptide concentration.34 Several OT
analogues were analyzed for functional selectivity and biased
properties; among these analogues, dOTK (2) was able to
activate the Gq pathway with a maximal eﬀect similar to that of
OT (1).34 Here, OT (1) and dOTK (2) full concentration−
response curves for OTR/Gq activation were generated (Figure
2D). Data were best ﬁtted by a four-parameter logistic model
for monotonic curves, with a resulting EC50 of 4.0 ± 1.6 nM
(SE) for dOTK (2), a value that is comparable with that
obtained for OT (1), EC50= 2.1 ± 1.3 nM (SE) (Table 1).
dOTK (2) and OT (1) thus present identical pharmacological
properties toward OTR/Gq activation, validating the choice of
the dOTK (2) analogue as a parent structure for the bivalent
synthesis. Interestingly, OT (1) and dOTK (2) curves revealed
comparable Hill coeﬃcients (−0.49 for OT (1) and −0.51 for
dOTK (2)) statistically diﬀerent from −1 (P < 0.05) (Table 1),
suggesting the activation of a nonhomogeneous population of
OTRs.
The bivalent ligand series was then evaluated with the Gq
BRET biosensor. As shown in Figure 2E, the concentration−
response curves of dOTK2−C6 (4a), dOTK2−C12 (4d), and
dOTK2−C14 (4e) were again monotonic and could be best
ﬁtted with a classical logistic model, with a Hill coeﬃcient
diﬀerent from −1 (P < 0.05) (Table 1). On the contrary, the
two bivalent ligands, dOTK2−C8 (4b) and dOTK2−C10 (4c),
promoted Gq activation with a biphasic behavior that could be
best ﬁtted by a model for biphasic dose−response curves
assuming a Hill coeﬃcient equal to −1 for both phases. The
resulting EC50 for dOTK2−C8 (4b) and dOTK2−C10 (4c)
(Table 1) indicated a ﬁrst activation process with an EC50Hi in
the pico-molar range (EC50Hi = 0.8 ± 0.7 pM (SE) for
dOTK2−C8 (4b) and EC50Hi = 2.8 ± 1.9 pM (SE) for
dOTK2−C10 (4c)) and a second activation process with an
EC50Lo in the high nanomolar range (EC50Lo= 67.3 ± 17.9 nM
(SE) for dOTK2−C8 (4b) and EC50Lo= 13 ± 5.5 nM (SE) for
dOTK2−C10 (4c)).
Statistical analysis of the maximal activation values (Emax)
(Table 1), indicated that the Emax values of the bivalent
analogues were not statistically diﬀerent from that of dOTK
(2), suggesting that dOTK (2) and the bivalent compounds
(4a−e) activated the same pool of receptors.
Finally, we assayed the contribution of the spacer by
synthesizing the monovalent dOTK-C8 (3) analogue. As
shown in Figure 2D, dOTK-C8 (3) generated a monophasic
activation curve with a calculated EC50 of 4.1 ± 4.6 nM (SE)
and a Hill coeﬃcient = −0.50 statistically diﬀerent from −1 (P
< 0.05), comparable to those of dOTK (3) (4.0 ± 1.6 nM (SE),
Hill coeﬃcient = −0.51, and OT (1) (2.1 ± 1.3 nM (SE), Hill
coeﬃcient = −0.49). We can therefore exclude a signiﬁcant
contribution to the biphasic activation process of the spacer
alone.
The binding features of dOTK (2) and dOTK2−C8 (4b) to
the OTR were then investigated in competition binding
experiments (Figure 3). dOTK2−C8 (4b) data were best ﬁtted
with a biphasic curve characterized by a high aﬃnity (KiHi =
0.08 ± 0.05 pM (SE)) and low aﬃnity component (KiLo = 1.24
± 0.6 nM (SE)), in agreement with BRET curves. dOTK (2)
could be ﬁtted by a two-site binding model (P < 0.01) with KiHi
of 21 ± 6.93 pM (SE) and a KiLo of 3.35 ± 2.07 nM (SE)
(Figure 3). KiHi and KiLo values obtained in binding assays
resulted in being left-shifted by a factor of 10 with respect to
EC50Hi and EC50Lo values obtained in activation experiments, a
phenomenon that can result from the diﬀerent nature of the
assays performed (binding is performed in competitive
conditions using as a radioligand a monovalent antagonist,
while activation is a noncompetitive assay) and/or by the
experimental conditions in which the two assays were
performed (temperature, buﬀers, and incubation times).
Table 1. Pharmacological Parameters of Monovalent and Bivalent Ligands at the WT OTRa
EC50 (mean ± SE) Hill coeﬃcient (mean ± SE) Emax (mean ± SE) n
OT (1) 2.1 ± 1.3 nM −0.49 ± 0.10 −0.11 ± 0.006 3
dOTK (2) 4.0 ± 1.6 nM −0.51 ± 0.07 −0.11 ± 0.005 5
dOTK (2) (*) EC50Hi 265 ± 89 pM ﬁxed −1 −0.10 ± 0.003 5
EC50Lo 74.8 ± 67 nM ﬁxed −1
dOTK-C8 (3) 4.1 ± 4.6 nM −0.50 ± 0.09 −0.11 ± 0.008 3
dOTK2−C6 (4a) 11.78 ± 1.7 nM −0.67 ± 0.09 −0.13 ± 0.005 3
dOTK2−C8 (4b) EC50Hi 0.8 ± 0.7 pM ﬁxed −1 −0.11 ± 0.004 5
EC50Lo 67.3 ± 17.9 nM ﬁxed −1
dOTK2−C10 (4c) EC50Hi 2.8 ± 1.9 pM ﬁxed −1 −0.10 ± 0.004 3
EC50Lo 13 ± 5.5 nM ﬁxed −1
dOTK2−C12 (4d) 20.1 ± 11.5 nM −0.74 ± 0.19 −0.11 ± 0.007 3
dOTK2−C14 (4e) 29.4 ± 11.6 nM −0.68 ± 0.24 −0.10 ± 0.010 4
aParameters obtained in BRET experiments (Figure 2) describe the activity of monovalent and bivalent agonists on Gq signaling in wild type (WT)
OTR. Data were analyzed by a four-parameters logistic model for monotonic curves or by a seven-parameter model for biphasic curves. For biphasic
ﬁtting, in which the Hill coeﬃcient was ﬁxed equal to −1 for both phases, EC50Hi refers to the “high” potency site and EC50Lo to the “low” potency
site. Estimated parameter values represent means ± SE of three-ﬁve independent experiments performed at least in triplicate. (*) Biphasic ﬁtting of
dOTK (2) data.
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Binding and activation data suggest the coexistence of
diﬀerent receptor subpopulations, a concept observed before in
single molecule studies looking at other receptors.35,36
Although alternative explanations could in principle arise
from cooperativity, no available model based on such a
mechanism is able to account at the same time for biphasic
binding and activation. Moreover, only negative cooperativity
has been reported for the OTR.37 Since the most plausible
explanation of our observations is thus the presence of diﬀerent
receptor subpopulations, we analyzed the pharmacological
features of the activation curves by dissecting their possible
components (Figure 4).
dOTK (2) activation, although best ﬁtted by a monotonic
curve, is characterized by a Hill coeﬃcient = −0.51 in the
BRET assay. As shown in Figure 4B (dashed black lines, whose
sum is the continuous black line), this same activation curve
can be broken up as a sum of two independent decays with Hill
coeﬃcient = −1, resulting in two EC50 (EC50Hi and EC50Lo)
diﬀering by up to 2 orders of magnitude. Direct comparison of
the EC50Hi and EC50Lo between dOTK (2) and dOTK2−C8
(4b) shows that while the EC50Lo values (dOTK (2), 74.8 nM;
dOTK2−C8 (4b), 67.3 nM) are statistically not diﬀerent, the
EC50Hi values (dOTK (2), 265 pM; dOTK2−C8 (4b), 0.8 pM)
are signiﬁcantly diﬀerent (Table 1). Consistently, our binding
studies show low aﬃnity sites with identical Ki values for dOTK
(2) (1.24 nM) and dOTK2−C8 (4b) (3.35 nM) and a high
aﬃnity site with 2 orders of magnitude diﬀerent Ki values for
dOTK (2) (21 pM) and dOTK2−C8 (4b) (0.08 pM). These
data indicate that the OTR exists in (i) a high aﬃnity state
whose aﬃnity is markedly boosted only by bivalent ligands and
(ii) a low aﬃnity state that does not discriminate between
monovalent and bivalent analogues. On the basis of this
evidence, we hypothesize that the ﬁrst component of the
bivalent activation curve is sustained by high aﬃnity sites,
Figure 3. Binding properties of dOTK and dOTK2-C8. Binding
properties of dOTK (1) and dOTK2−C8 (4b) were determined by
competition experiments on membranes of COS7 cells transfected
with the OTR. Membranes were incubated with 10 pM [125I]−OVTA
in the presence of increasing concentrations of dOTK (1) (in black)
or dOTK2−C8 (4b) (in magenta); nonspeciﬁc binding was
determined in the presence of OT (1 μM). Data points are
represented as the mean ± SEM of three (dOTK) and six
(dOTK2−C8) independent experiments each performed in triplicate.
[L] ligand concentration.
Figure 4. Analysis of the BRET OTR/Gq activation curves. (A) Sketches of the molecules used in this study: monovalent dOTK (1) and bivalent
dOTK2−C8 (4b) ligands, and monomeric and dimeric OTR. (B) OTR activation curves as measured by the BRET biosensor vs the log of the
concentration of monovalent (black dots) and of bivalent ligands (magenta dots). Continuous lines represent the best ﬁttings obtained by the sum of
two linear processes. Dashed black lines represent separately the two single linear processes added to obtain the best ﬁt. [L] is the ligand
concentration. (C) Cartoon description of the dose-dependent steps of dimeric and monomeric OTR activation by the monovalent ligand; left
panel, dOTK (2) concentrations at which no detectable activation is observed; middle panel, intermediate dOTK (2) concentrations at which
activation is compatible with binding to one or to both sites of dimeric OTR, two possibilities that cannot be discerned in this study (Supporting
Note 1); and right panel, activation of monomeric OTR at high dOTK (2) concentration. (D) Cartoon description of the dose-dependent stages of
dimeric and monomeric OTR activation by the bivalent ligand. Left panel: dOTK2−C8 (4b) concentrations at which no detectable activation is
observed; intermediate panel, activation of the dimeric OTR at low dOTK2−C8 (4b) concentrations, compatible with a process in which the binding
of the ﬁrst pharmacophore constrains the second one within a volume (V), allowing the docking of the bivalent ligand into the two binding sites of a
dimeric OTR; and right panel, activation of monomeric OTR at higher dOTK2−C8 (4b) concentrations.
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corresponding to dimeric receptors, that are activated in a dose-
dependent way at concentrations between 10−13 and 10−11 M;
the maximal activation of these sites is achieved at 10−11 M, and
from 10−11 to 10−9 M, the curve stays ﬂat, as expected for a
saturating phenomenon. At 10−9 M, a population of low aﬃnity
sites, corresponding to monomeric receptors, starts to be
activated, leading to the second component of the biphasic
curve; these sites are activated in a dose-dependent way at
concentrations between 10−9 and 10−7 M.
Because these data strongly suggest that the high aﬃnity sites
correspond to dimeric receptors, while the low aﬃnity sites
correspond to monomeric receptors, we engaged in receptor
modeling and docking analysis to identify the monomeric and
dimeric receptor conformations sustaining monovalent and
bivalent binding and activation.
Molecular Modeling and Docking of Monovalent and
Bivalent dOTK Ligands into Monomeric and Dimeric
OTR. The molecular models for monomeric OTR complexed
with dOTK (2) (Figure S1) and protomers of dimeric OTRs
complexed with bivalent dOTK2−C8 were developed (Figure
5) (for details, see Supporting Information).
Our docking studies suggest that the monomeric OTR binds
OT (1) and dOTK (2) in a region between the extracellular
loops (ECLs) and extracellular ends of the transmembrane
helices (TMHs).30,38 The model (Supporting Information)
implicates the following ligand/receptor amino acid pairs
involved in the binding of dOTK to the OTR (in the binding
pocket): Tyr2/Tyr200-Phe291; Ile3/Met123-Leu201-Ile201;
Gln4/Ser298; Asn5/Gln119-Gln295; and Lys8/(Glu42)-
Asp100. This docking also supports an orientation of the
ligand’s C-terminal tail toward the ECL1/extracellular part of
TMH1 and the cyclic dOTK ring in the transmembrane region
close to the ECL2 (see Figure S1 for details and Supporting
Information, Experimental Section for the list of amino acids
constituting the ligand-binding pocket).
Stimulated by experimental evidence that suggests diﬀerent
protomer−protomer interfaces in diﬀerent GPCR dimers,39−43
we designed two models of OTRs protomer−protomer
interfaces, either constituted by amino acid side chains between
TMH1-TMH2-helix8 (Figure 5A) or between TMH5-TMH6
(Figure 5B). Remarkably, only the OTR dimers with a
protomer interface at TMH1-TMH2-helix8 allow for the
computational binding of both moieties of our homobivalent
C8 (4b) and C10 (4c) ligands into the two orthosteric binding
sites (Figure 5A and B). Of note, the docking of dOTK-C8
(4b) inside dimers with a TMH1-TMH2-helix8 protomer−
protomer interface is possible thanks to the presence of a
channel-like passage between the two interacting helices
(TMH1-TMH2) (Figure 5C). This channel-like passage allows
the docking of the C8 (Figure 5A) and C10 spacers
maintaining the pharmacophore binding mode of the
monomeric OTR/dOTK complex. In this model, the channel
opening toward the membrane is mainly constituted at the
protomer surface by Ala39, Val43, Leu97, and Leu98 and is
accompanied by further residues of ECL1, such as Ile101.
Indeed, the presence of a shortcut channel is crucial to combine
the limited length of C8 and C10 spacers with the intrinsic size
of the OTR and an optimal docking of dOTK (2) into the
orthosteric binding sites. This fact can be immediately
recognized by analyzing Figure 5D, which shows that the
conformation adopted by the spacers to connect the two dOTK
pharmacophores is almost linear. No alternative arrangements
of dOTK2−C8 (4b) and dOTK2−C10 (4c) into a dimerized
OTR appear possible: any connection between the binding
sites external to TMHs would have required a much longer
spacer. The OTR/dOTK arrangement in the TMH1-TMH2-
helix8 dimer is also supported by the fact that the C6 spacer is
too short, leading to an extraction of the ligand-moieties from
the orthosteric binding sites in the protomers. Likewise, by
constraining ligand moieties with the C12 and C14 spacers
inside the orthosteric binding sites, the conformation of the
spacers within the channel would become kinked (Figure 5D),
suggesting that their excessive length could prevent appropriate
binding at the dimer by steric hindrance. A model based on
TMH5-TMH6 (Figure 5B) will also require a much longer
spacer, as the estimated straight linear distance between the two
orthosteric binding sites is, in this case, approximately 50 Å;
however, as the spacer would lay above the ECLs regions, its
length will need to be further increased, with a high probability
that a very long alkane chain will negatively impact docking and
binding for its higher hydrophobicity.
Figure 5. Structural homology model of the OTR dimer interfaces and
docking of the bivalent dOTK2-C8 (4b). (A) OTR dimers with a
putative TMH1-TMH2-helix8 interface. Crystal structures of κ-opioid
receptor (KOR), β-1 adrenergic receptor, and opsin suggest a
protomer−protomer arrangement with a contact interface among
TMH1-TMH2-helix8. The dimeric-conformation of the κ-opiod
receptor (PDB entry 4DJH, insert window) was used to build the
OTR dimer with a TMH1-TMH2-helix8 interface. This arrangement
provides a suitable model to dock both moieties of the homobivalent
ligand into the orthosteric binding-sites. (B) A hypothetical OTR
TMH5-TMH6-ICL2 dimer arrangement, suggested by the crystallized
CXCR4 dimer (insert window, yellow backbone), did not allow for the
docking of the two moieties of dOTK2−C8 (4b) into the putative
orthosteric binding sites. (C) The side-chains of dOTK moieties at
position 8 engage into a channel-like opening between TMH1 and
TMH2 (inner surface, clipped), and the C8 spacer runs into a channel-
like protomer−protomer connection. (D) In contrast to C8 (magenta
sticks), extended spacers such as C14 (gray) would not sterically ﬁt
between the interacting helices of the OTR. In a constrained
constellation in which the protomer−protomer distance is held during
dynamic movement of the C14 spacer only, the benched C14 spacer is
unable to engage the channel opening at the interacting helices. H,
helix; Ntt, N-terminal tail; E, extracellular loop.
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Our modeling predicted that receptor mutations of the
dimeric TMH1-TMH2-helix8 interface and/or synthetic
peptides mimicking TMH1 would interfere with a channel
constitution, altering the critical relationship between the
channel length and the length of the C8 and C10 spacers. If
either were altered, then we predicted this would abolish the
reduced entropic cost linked to the favorable docking, resulting
in the loss of superactivity. Experimentally, if unable to dock
into the two orthosteric sites of a receptor dimer, we expect the
C8 and C10 bivalent ligands to lose the ﬁrst, high potency
phase of the activation curve. To speciﬁcally test this
hypothesis, we used a series of point mutations in the
TMH1-TMH2-helix8 interface of OTR dimers and synthetic
peptides interfering with the TMH1 and TMH5 dimer
interfaces.
Point Mutations at the TMH1 Dimer Interface and a
Synthetic Peptide Mimicking TMH1 Modiﬁes the
Activation Induced by Bivalent dOTK Ligands. Receptors
bearing single or combined mutations of all residues exposed at
the TMH1-TMH2-helix8 interface (C47, V43, L50, L51, L97,
L98, V341, and V345) were preliminarily evaluated for their
expression at the cell surface by ﬂuorescence microscopy assays
(Figure S2) and FACS analysis (Figure S3). We found that
receptors bearing multiple mutations at the TMH1-TMH2-
helix8 interface were retained inside the intracellular compart-
ments. Only, the OTR C47A and OTR V43A/C47A receptor
mutants were found to be correctly localized and expressed at
the plasma membrane where they formed dimers (Figure S4)
and were further characterized.
The OTR C47A and OTR V43A/C47A (Figure 6A) were
probed with the full C6−C14 bivalent series (4a−e) (Figure
6B,C). In the OTR C47A, the C6, C8, and C10 bivalent ligands
presented monophasic activation curves (Hill coeﬃcient
diﬀerent from −1, P < 0.05), all rightward shifted with respect
to that of dOTK (2) (Table 2). Intriguingly, the bivalent
ligands with longer spacers, C12 (4d) and C14 (4e), displayed
a biphasic trend at this mutant, with a calculated EC50Hi < 10
pM and EC50Lo > 100 nM (Figure 6B and Table 2). In the
OTR mutant V43A/C47A, only the bivalent ligand with the
longest spacer, dOTK2−C14 (4e), activated Gq with a biphasic
curve with calculated EC50Hi of 11 ± 14 pM (SE) and EC50Lo of
867 ± 250 nM (SE) (Figure 6C and Table 2). These data
suggest that perturbing the TMH1-TMH2-helix 8 interface and
the spacer channel opening between the helices at residues C47
and V43 “relaxes” or “stretches” the dimers allowing enhanced
binding and functional activity of bivalent analogues with
increased spacer lengths but excludes the biphasic eﬀects of C8
(4b) and C10 (4c) observed in the OTR wild type (WT). We
conclude that these two point mutations most likely lead to a
weakening in protomer−protomer interactions with a con-
sequent rearrangement between the protomers which, in turn,
causes a shift in the spacer-length required to enable the
binding of two dOTK pharmacophores into both orthosteric
sites.
To ensure that these results are indeed due to protein−
protein interactions, we used synthetic peptides mimicking
single transmembrane helices, an approach previously shown to
destabilize in vitro and in vivo the quaternary structure and the
interaction interfaces of heterodimeric GPCR44−48 and
rhodopsin.49 Cells were incubated with TMH1 and TMH5
peptides fused at their C-terminal end with a portion of the
HIV transactivator of transcription (TAT) sequences to
promote their integration and correct orientation in the plasma
membrane.50
First, we tested the interference of TMH1 and TMH5
(Figure 7A) with the OTR dimer formation/stabilization in
cells transfected with OTR-GFP2 and OTR-Rluc (Figure 7B).
As shown in Figure 7B, incubation with TMH1-TAT and
Figure 6. Functional properties of monovalent and bivalent analogues
at C47A and V43A/C47A OTR mutants at the dimeric TMH1/
TMH2 OTR interface. (A) The OTR dimer model reveals potential
protomeric contacts constituted by hydrophobic amino acids mainly
located between TMH1 and TMH2, respectively. Valine in position 43
(V43, in green) and cysteine in position 47 (C47, in red) both
localized on TMH1 are reported in the inset. H, helix; E, extracellular
loop; Ntt, N-terminal tail. (B) Gq activation was measured by BRET
in HEK293 cells coexpressing Gαq-RLuc8, GFP
10-Gγ2, Gβ1, and C47A
or (C) V43A/C47A OTR mutants. Cells were left untreated or
stimulated with increasing concentrations of the indicated agonists.
Data are expressed as the diﬀerence in the BRET signal measured in
the absence and presence of the agonist and are shown as the means ±
SEM of three-four independent experiments performed in triplicate.
The background of graphs reporting biphasic responses is colored in
light-orange. Bivalent dOTK2−C8 (4b) and dOTK2−C10 (4c)
activation curves are in magenta.
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TMH5-TAT resulted in a reduction of the maximal BRET of
36% and 30%, indicating that both peptides induced a
destabilization of the OTR dimers/oligomers. The residual
BRET signal observed in the presence of both TMH1-TAT and
TMH5-TAT is consistent with the coexistence of two dimeric
subpopulations characterized by a TMH1 or a TMH5 interface;
in addition, it is likely that the peptides disrupt the quaternary
structure between the receptors but do not necessarily block
dimerization completely. Thus, a component of this residual
maximal BRET could arise from dimeric/oligomeric receptors
that cannot be modulated by exogenous peptides, such as those
residing in intracellular compartments. Importantly, there was
no measurable decrease in the BRET signal in the presence of a
control transmembrane peptide TMH1C-TAT, in which all
residues exposed to the putative interacting interface of TMH1
have been changed into alanine. These results conﬁrm the
speciﬁcity of the functional interference exerted by the TMH1-
TAT and TMH5-TAT peptides on OTR dimers/oligomers.
Next, we tested the eﬀects of the bivalent ligands in the
presence of TMH1-TAT or TMH5-TAT. If the superagonist
eﬀects were indeed due to binding to two separate receptors in
a dimer, then disruption of the quaternary structure with the
disrupting peptides should lead to a monophasic response
curve. If, however, the bivalent ligands are binding to two sites
on the same receptor or binding a single receptor in a novel
orthosteric site (Figure 4D panel V), then the peptides should
have no eﬀect on the response curve. As shown in Figure 7C,
the addition of TMH1-TAT completely disrupts the biphasic
response of bivalent ligands which now present monophasic (P
< 0.05) activation curves (Hill coeﬃcient in the range 0.41−
0.59; Table 3). Moreover, the EC50 values were all rightward
shifted with respect to that of dOTK (2) (Table 3). On the
contrary, no eﬀect of TMH5-TAT was observed on the
biphasic response (P < 0.05) of the activation curves (Figure
7D) and on activation parameters (Table 3) of bivalent ligands.
Finally, neither TMH1 nor TMH5 aﬀected the activation
properties of the monovalent dOTK (2) ligand.
These data solidify the model presented in Figure 4 and
demonstrate that the high aﬃnity state of the OTR targeted by
the C8 (4b) and C10 (4c) bivalent analogues are the dimers
having a TMH1/TMH2 interface.
Potency of dOTK2−C8 in Vivo on Social Behavior.
OTR agonists are currently in clinical trial for autism related
disorders.51 To test whether a bivalent OTR ligand may be
clinically relevant, we tested dOTK2−C8 (4b) in vivo in two
animal models in which the pharmacological eﬀects of OT
agonists on social behavior have been previously extensively
characterized.
The ﬁrst model is represented by genetically modiﬁed mice
in which one allele coding for the mouse OTR gene (Oxtr) has
been deleted; as previously reported, Oxtr+/− mice display a
deﬁcit in social behavior.52 In particular, when tested for
sociability in the three chamber test (Figure 8A), these animals
spent an equal amount of time exploring the compartment
occupied by a stranger mouse and that occupied by an empty
cage, with a resulting diﬀerence score, calculated as the
diﬀerence between the time spent in the chamber with the
stranger and the time spent in the chamber with the empty
cage, close to zero (Figure 8B and C). As previously reported,52
a single dose of OT (1) of 0.5 ng/mouse administered i.c.v.
immediately prior to the test corrected this abnormal behavior
by signiﬁcantly increasing the time spent exploring the stranger
mouse over the time spent exploring the empty cage, as
indicated by a signiﬁcant increase in the diﬀerence score [OT
(1): F(3,36) = 20.53, P < 0.001] (Figure 8B). To assess the
eﬀects of dOTK2−C8 (4b) on social behavior, we administered
this compound i.c.v. to male Oxtr+/− mice. As shown in Figure
8C, dOTK2−C8 (4b) signiﬁcantly restored sociability, i.e.,
signiﬁcantly increased the time spent exploring the unfamiliar
mouse over the time spent exploring the empty cage, already at
a dose of 0.005 ng/mouse [dOTK2−C8 (4b): F(3,36) = 14.16,
P < 0.001]. The dose of 0.05 ng/mouse was statistically
diﬀerent from 0.005 ng/mouse (P < 0.05) but not from 0.5 ng/
mouse. These data indicate that dOTK2−C8 is active at a 100-
Table 2. Characterization of Monovalent and Bivalent Ligands Function at C47A and V43A/C47A OTR Mutantsa
EC50 (mean ± SE) Hill coeﬃcient (mean ± SE) Emax (mean ± SE) n
C47A
dOTK (2) 2.8 ± 0.7 nM −0.54 ± 0.10 −0.15 ± 0.008 3
dOTK2−C6 (4a) 21.9 ± 18.3 nM −0.43 ± 0.12 −0.13 ± 0.01 3
dOTK2−C8 (4b) 40.5 ± 9.4 nM −0.61 ± 0.07 −0.14 ± 0.006 3
dOTK2−C10 (4c) 21.7 ± 85 nM −0.42 ± 0.12 −0.14 ± 0.019 3
dOTK2−C12 (4d) EC50Hi 1.2 ± 0.7 pM ﬁxed −1 −0.13 ± 0.012 3
EC50Lo 135 ± 53.6 nM ﬁxed −1
dOTK2−C14 (4e) EC50Hi 1.4 ± 3.5 pM ﬁxed −1 −0.11 ± 0.008 3
EC50Lo 301 ± 194 nM ﬁxed −1
V43A/C47A
dOTK (2) 33.4 ± 11 nM −0.73 ± 0.11 −0.08 ± 0.003 3
dOTK2−C6 (4a) 25.6 ± 9.8 nM −0.53 ± 0.14 −0.14 ± 0.013 3
dOTK2−C8 (4b) 117.2 ± 44.9 nM −0.78 ± 0.19 −0.10 ± 0.007 3
dOTK2−C10 (4c) 40.55 ± 18.5 nM −0.66 ± 0.20 −0.14 ± 0.013 3
dOTK2−C12 (4d) 182 ± 30.6 nM −0.78 ± 0.16 −0.08 ± 0.006 4
dOTK2−C14 (4e) EC50Hi 11 ± 14 pM ﬁxed −1 −0.11 ± 0.007 4
EC50Lo 867 ± 250 nM ﬁxed −1
aParameters obtained in BRET experiments (Figure 6) describe the activity of monovalent and bivalent agonists on Gq signaling in mutant OTRs.
Data were analyzed by a four-parameter logistic model for monotonic curves or by a seven parameter model for biphasic curves. For biphasic ﬁtting,
the Hill coeﬃcient was ﬁxed equal to −1 for both phases, EC50Hi refers to the “high” potency site, and EC50Lo to the “low” potency site. Estimated
parameter values represent the mean ± SE of three-four independent experiments performed at least in triplicate.
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fold lower dose in comparison to that of the endogenous
peptide OT in restoring sociability in Oxtr+/− mice.
The second model is represented by the shoaling behavior of
zebraﬁsh, a social behavior that we have previously shown to be
modulated, in this vertebrate, by several OT-related peptides53
(Figure 8D). We demonstrated that the total time spent by WT
zebraﬁsh swimming parallel to conspeciﬁcs is greater than that
spent shoaling in proximity of Nacre, a mutant zebraﬁsh with a
defect in pigmentation. When this parameter was expressed as a
diﬀerence in the time spent by the test animal with each
phenotype (Nacre−WT), it was negative in vehicle treated
animals. As shown in Figure 8E and as previously reported,53
treatment with isotocin (IT), the analogue of OT in ﬁsh,
injected into the caudal musculature signiﬁcantly increased the
time spent in proximity to Nacre at a concentration of 0.75 ng/
kg, with a consequent signiﬁcant decrease in the diﬀerence in
the time (Nacre-WT) that becomes positive, indicating that the
ﬁsh prefer to shoal in proximity to Nacre than to WT [IT:
F(4,45) = 34.00, P < 0.001].
As shown in Figure 8F, dOTK2−C8 (4b) signiﬁcantly
increased the shoaling preference to Nacre, i.e., signiﬁcantly
increased the time spent swimming parallel to Nacre over the
time spent shoaling close to the conspeciﬁc already at a dose of
0.02 ng/kg [F(6,63) = 17.78, P < 0.0001]. The dose of 0.2 ng/
kg was statistically diﬀerent from the lower doses 0.002 and
0.02 ng/kg but not from 0.5, 0.75, and 1 ng/kg. These data
indicate that dOTK2−C8 (4b) is active at approximately a 40-
fold lower dose as compared to the endogenous peptide IT on
zebraﬁsh sociability in vivo. The slightly lower potency of
dOTK2−C8 (4b) in zebraﬁsh compared to that of mice can be
ascribed either to the diﬀerences between the involved zebraﬁsh
receptor (native ligand IT) and the mouse receptor (native
ligand OT (1)) across species and/or to the administration
route employed (dOTK2−C8 (4b) was administered i.c.v. in
mice and i.m. in zebraﬁsh).
■ DISCUSSION
Despite the promise of GPCR dimers as drug targets, clinically
relevant molecules speciﬁc to homo-oligomers have not yet
been reported. In this study, we report the synthesis and
characterization of a series of homobivalent agonistic ligands in
which two identical oxytocin-derived peptides were linked by
aliphatic spacers of increasing length. Using this series of
compounds, we are able to show that (i) the OTR exists in
both low aﬃnity and high aﬃnity states that most likely reﬂect
changes in oligomeric assembly; (ii) the low aﬃnity site is
indiﬀerent to the spacer length of the bivalent ligands; (iii) the
high aﬃnity population achieves superagonistic responses upon
binding of bivalent ligands having a speciﬁc spacer length (C8−
C10; ∼ 25 Å), indicating the presence of a receptor entity with
a speciﬁc structure; (iv) mutagenesis and TMH interference
assays experimentally show that this structure is represented by
homodimes interacting via a TMH1-TMH2 interface; and (v)
dimeric OTR can be exploited in vivo as a drug target of
homobivalent based therapeutic strategies.
The development of bivalent ligands such as those shown
here requires matching the spacer lengths of bivalent ligands
with the distance between the receptor protomers. In the OTR,
this eﬀect is dependent on the proposed “channel-like passage”,
which determines and constrains the length of the bivalent
spacer and prevents biphasic activation for bivalent analogues
with shorter or longer spacers. This channel-like passage is a
feature that emerges in the model only when a speciﬁc dimeric
arrangement based on a TMH1-TMH2 interface is adopted;
the relevance of the channel and involvement of the TMH1
interface in an active dimeric conformation targeted by bivalent
ligands was predicted by our modeling data indicating that
modiﬁcation of single residues located in TMH1 prevent
bivalent docking into the OTR dimer. This model has been
Figure 7. Interference properties of synthetic transmembrane peptides
on OTR homodimerization and activation. (A) Primary sequence of
OTR transmembrane (TMH1 and TRMH5) synthetic peptides C-
terminally fused to a portion of the highly polar HIV transactivator of
transcription (TAT, in red) (GRKKRRQRRR). TMH 1C, in which all
residues exposed to the putative interacting interface of TMH1 have
been changed into alanine, was used as the control. (B) To test
synthetic transmembrane peptide eﬀects on OTR homodimerization,
cells were transfected with OTR-Rluc (3 μg) and OTR-GFP2 (9 μg)
and incubated with the indicated TMHs used at 1 μM for 1 h. Values
are represented as the means ± SEM of at least three independent
experiments. ***P < 0.001 versus the corresponding not treated (NT)
cells. (C) Gq activation was measured by BRET in HEK293 cells
coexpressing Gαq-RLuc8, GFP
10-Gγ2, Gβ1, and OTR. Cells were
preincubated with 1 μM TMH1 or (D) 1 μM TMH5 for 2 h and then
left untreated or stimulated with increasing concentrations of the
indicated agonists. Data are expressed as the diﬀerence in the BRET
signal measured in the absence and presence of the agonist and are
shown as the means ± SEM of three to four independent experiments
performed in triplicate. The background of graphs reporting biphasic
responses is colored in light-orange. Bivalent dOTK2−C8 (4b) and
dOTK2−C10 (4c) activation curves are in magenta.
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validated by interference experiments with synthetic peptides
mimicking transmembrane helices and mutagenesis data of key
residues located at the TMH1-TMH2 interface in which we
observed a loss of the superagonist eﬀects of dOTK2−C8 (4b)
and dOTK2−C10 (4c) but a gain in the superagonist eﬀects of
dOTK2−C12 (4d) and dOTK2−C14 (4e). This behavior is
coherent with a weakening in the TMH1 protomer−protomer
interactions induced by these mutations, which may include
mutual azimuthal rotation. The channel passage described here
could be of general interest: the search and characterization of
channel-like opening(s) might be an important step in the
design of superactive bivalent ligands for other members of the
GPCR superfamily, with broad applications for drug design and
development.
A key question concerns the mechanism responsible for the
boost in EC50Hi observed for the superactive bivalent ligands
docking into the TMH1-TMH2 dimer. A reduction in the
entropy cost for bivalent ligands (and an increase in binding
aﬃnity) is expected when their two pharmacophores,
connected by a spacer of length L, are both able to bind to
the docking sites of a dimeric receptor.54,55 Indeed, the docking
of the ﬁrst pharmacophore constrains the second one within a
volume (V) that could be roughly approximated as a
hemisphere of radius L. Here, L ≈ 25 Å, is the distance
between the C-alpha atoms of the two lysine residues present in
dOTK2−C8 (4b) and thus includes the C8 spacer plus the
lateral chains of the two lysine residues (Figure 1 and Figure
4D). Inside V, the eﬀective local concentration (CLOC) of the
unbound pharmacophore is roughly CLOC ≈ 50 mM. Since at
such high concentrations the second pharmacophore becomes
fully bound to the receptor, the condition of single
pharmacophore binding of a bivalent ligand to a dimeric
receptor is unstable. This eﬀect can be formally expressed in
terms of a reduced entropy cost for the binding of bivalent
ligands, leading to a markedly enhanced binding aﬃnity. Its
analysis also enables the formulation, under a few simplifying
assumption, of a simple expression for the expected activation
eﬃciency of bivalent ligand: EC50Hi ∼ (EC50Lo)2/CLOC
(Supporting Note 2). This simple estimate is veriﬁed by our
data, supporting the notion that the huge increase in potency
intrinsically brought about by the double docking is the
dominant factor in our observations, overshadowing other
eﬀects of less quantitative relevance.
Emerging data indicate that in GPCRs diﬀerent interfaces
can be found in diﬀerent oligomers and even in diﬀerent
conformations (activity states) of the same oligomer.3,35 For
example, molecular simulation of β1- and β2-adrenergic
receptor homodimer stability in a lipid bilayer is consistent
with a model of oligomerization in which more stable TMH1
homodimers diﬀuse through the membrane, transiently
interacting with other protomers at interfaces involving other
TMH helices (e.g., TMH4).56 The data obtained in this work
suggest that the OTR also exists in at least two dimeric
conformations, one involving a TMH1/TMH2 interface and
the other a TMH5 interface, and that only the TMH1/TMH2
dimers can be activated by the bivalent ligands with increased
aﬃnity and potency. Importantly, the analysis of the amplitude
of the ﬁrst phase of the dOTK2−C8 (4b) and dOTK2−C10
(4c) biphasic activation curves allowed for the computation of
the fraction of the TMH1/TMH2 dimeric OTR speciﬁcally
targeted by the bivalent compounds. The amplitude of the ﬁrst
phase of the dOTK2−C8 (4b) and dOTK2−C10 (4c) biphasic
curves, expressed as the percentage of the maximal amplitude of
the curve (Emax values reported in Table 2), resulted in 32 ±
0.5% (SE) and 44 ± 0.5% (SE), suggesting that, in our
experimental conditions, the dimeric OTR population targeted
by the superactive bivalent ligand ranges between 32 and 44%
of all activable OTR present in the cells, a percentage in line
with previous single molecule attempts to measure oligomeri-
zation.57,58 To quantitatively disclose dimeric entities in living
cells is currently a very critical issue in the GPCR ﬁeld as the
techniques employed to determine the composition of
monomeric/oligomeric GPCRs, including resonance energy
transfer (RET), ﬂuorescence lifetime imaging (FLIM), total
internal reﬂected ﬂuorescence (TIRF), ﬂuorescence recovery
after photobleaching (FRAP), and ﬂuorescence correlation
spectroscopy (FCS), have led to a variety of diﬀerent results,
Table 3. Characterization of Monovalent and Bivalent Ligands Function in the Presence of Interfering TMH1-TAT and TMH5-
TAT Peptidesa
EC50 (mean ± SE) Hill coeﬃcient (mean ± SE) Emax (mean ± SE) n
+TMH1
dOTK (2) 0.92 ± 0.3 nM −0.57 ± 0.07 −0.15 ± 0.005 3
dOTK2−C8 (4b) 19.3 ± 9.1 nM −0.44 ± 0.07 −0.16 ± 0.011 4
dOTK2−C10 (4c) 17.3 ± 16.1 nM −0.41 ± 0.12 −0.15 ± 0.018 4
dOTK2−C12 (4d) 37.9 ± 12.1 nM −0.49 ± 0.14 −0.16 ± 0.018 3
dOTK2−C14 (4e) 15.4 ± 6.3 nM −0.59 ± 0.20 −0.144 ± 0.009 3
+TMH5
dOTK (2) 0.75 ± 0.3 nM −0.49 ± 0.12 −0.14 ± 0.008 3
dOTK2−C8 (4b) EC50Hi 11.8 ± 11.1 pM ﬁxed −1 −0.15 ± 0.002 3
EC50Lo 33.4 ± 11.9 nM ﬁxed −1
dOTK2−C10 (4c) EC50Hi 2.57 ± 1.5 pM ﬁxed −1 −0.17 ± 0.016 3
EC50Lo 11.0 ± 3.4 nM ﬁxed −1
dOTK2−C12 (4d) 14.0 ± 9.9 nM −0.40 ± 0.10 −0.15 ± 0.019 4
dOTK2−C14 (4e) 59.0 ± 23.1 nM −0.47 ± 0.11 −0.145 ± 0.011 3
aParameters obtained in BRET experiments (Figure 7) describe the activity of monovalent and bivalent agonists on Gq signaling in wild-type OTRs
in the presence of synthetic transmembrane peptides fused to the TAT peptide. Data were analyzed by a four-parameter logistic model for
monotonic curves or by a seven-parameter model for biphasic curves. For biphasic ﬁtting, the Hill coeﬃcient was ﬁxed equal to −1 for both phases,
EC50Hi refers to the “high” potency site and EC50Lo to the “low” potency site. Estimated parameter values represent the mean ± SE of three-four
independent experiments performed at least in triplicate.
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with no apparent consensus on what equilibrium among these
forms should be expected for each GPCR.3
Finally, to demonstrate the translational value of the
superactive OT analogues we used two well-established in
vivo models (social behavior in zebraﬁsh and mice) showing
that the homobivalent dOTK2−C8 (4b) ligand displays a
signiﬁcant gain (40- and 100-folds) over the endogenous
ligands, IT and OT (1). The increased potency of dOTK2−C8
(4b) in vivo is consistent with the presence of OTR dimers or
higher-order oligomers in native tissues, thus extending the
ﬁnding of OTR oligomers previously reported in the rat
mammary gland59 to the central nervous system. Remarkably,
the only slight decrease in potency observed in vivo in mice and
zebraﬁsh as compared to in vitro studies on human receptors
represent a proof of principle of the high value of these
analogues for translational studies in neurodevelopmental and
psychiatric disorders. As dOTK (2) binds with good aﬃnity
also to mouse V1a and V1b vasopressin receptors,60 dOTK2−
C8 (4b) could in principle also be hitting V1a and/or V1b
homodimers as well as OTR/V1a, OTR/V1b, or V1a/V1b
heterodimers. However, because we have previously shown that
the selectivity of dOTK (2) toward the OTR increases by a
factor 100 when the amino group of its lysine in position 8 is
no longer available,30 we believe that the selectivity proﬁle of
the bivalent dOTK2−C8 (4b) analogue toward the OTR could
be improved as well. In vivo experiments in vasopressin receptor
null models and/or with selective antagonists should be
performed to fully address this point.
In conclusion, this new bivalent ligand class shows great
potential in paving the way for the development of advanced
molecular tools and therapeutics targeting the OTR in
important diseases such as autism and schizophrenia. The
ﬁndings and methodology reported and developed here should
also be highly applicable to other GPCR signaling systems.
■ EXPERIMENTAL SECTION
Peptide Synthesis. Peptidic monovalent ligands were synthesized
on a CS Bio CS336X peptide synthesizer using Fmoc solid-phase
peptide synthesis (SPPS).61 Following cleavage from resin, peptides
were folded by air oxidation in 0.1 mol ammonium bicarbonate (pH
8.2) for 24 h. Peptides were analyzed and puriﬁed by analytical RP-
HPLC (Phenomenex Jupiter C18, 4 μm, 150 mm × 4.6 mm) using a
linear gradient of 0−60% B (solvent A, H2O/0.05% TFA; solvent B,
90% CH3CN/10% H2O/0.043% TFA) in 60 min at 1 mL/min while
monitoring UV absorbance at 214 nm. MS analysis was carried out on
an API 2000 from AB Sciex (Framingham, MA, USA). The purity of
all compounds was >95%. The bivalent ligands were synthesized via an
adapted method of Gera et al.62 that utilized a disuccinimidyl (DSS)
spacer to conjugate two monomers to form the bivalent ligand. Brieﬂy,
two equivalents of dOTK and one equivalent of the DSS spacer were
dissolved in anhydrous N,N-dimethylformamide (DMF), followed by
the addition of three equivalents of N,N-diisopropylethylamine
(DIEA) in anhydrous DMF to the solution. The reaction mixture
was left for 6 h and monitored by analytical RP-HPLC and LCMS. For
the compounds, where the DSS ester of the dicarboxylic acid was not
commercially available (C6 and C14), the DSS esters were created in
situ using N-hydroxysuccinimide (NHS) in the presence of N,N′-
diisopropylcarbodiimide (DIC) and DIEA, as described in ref 8.
Additional details on the synthesis can be found in Supporting
Information, Experimental Section.
OTR transmembrane (TMH) peptides were designed and
synthesized together with a portion of the highly polar HIV
transactivator of transcription, HIV TAT (GRKKRRQRRR), added
to the C-terminus of TMH peptides to aid in plasma membrane
insertion and correct orientation and to improve the peptide’s
solubility.50 Their sequences are shown in Figure 7A, and more details
are reported in Supporting Information, Experimental Section.
Cell Culture and Transfection. Human embryonic kidney 293
(HEK293) cells were purchased from the American Type Culture
Collection (Manassas, VA) and were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA)
supplemented with 5% (v/v) FBS (Sigma-Aldrich), 100 units of
penicillin (Sigma-Aldrich), 100 g/mL streptomycin (Sigma-Aldrich),
and 2 mM L-glutamine (Sigma-Aldrich). The day before transfection,
cells were seeded in 100 mm plates or 35 mm plates. Transient
transfections were performed using linear polyethyleimine 25 kDa
(PEI MW 25,000, Polysciences, Inc., Warrington, PA, USA) as
transfecting agent, at a ratio of 3 to 1 PEI/plasmid DNA. Twenty-four
hours after transfection, the supplemented DMEM was renewed, and
the cells were cultured for a further 24 h before the experiments.
BRET Assays. In the Gq BRET activation assay, DNA encoding for
Renilla Luciferase (Rluc8)-tagged Gαq (the BRET energy donor) (4
μg), GFP10-Gγ2 (BRET energy acceptor) (5 μg), Gβ1 (5 μg) G
proteins subunits, and OTR constructs (7 μg) were used. In OTR
dimerization experiments, a ﬁxed amount of OTR-Rluc (3 μg) and
saturating amount of OTR-GFP2 (9 μg) were used. HEK293 cells
were transfected as described i refs 33 and 34. Forty-eight hours
following transfection, cells were washed twice with PBS, detached,
and resuspended in PBS plus 0.1% (w/v) glucose at room
temperature. Protein concentration, was determined using a
Figure 8. Bivalent dOTK2-C8 peptide boosts social behavior in mice
and zebraﬁsh. (A) Eﬀect of OT (1) and dOTK2−C8 (4b) on
sociability in Oxtr+/− mice assayed in the three chamber apparatus.
Sociability (expressed as the diﬀerence score between the time spent in
proximity to a stranger and the empty cage) was evaluated 10 min
following i.c.v. injection of vehicle (V) or increasing doses (ng/mouse)
of (B) OT (1) or (C) dOTK2−C8 (4b). (D) Eﬀect of isotocin and
dOTK2−C8 (4b) on social preference in zebraﬁsh evaluated in a
shoaling preference test. Social preference is expressed in terms of
diﬀerence score between the time spent close to Nacre and that spent
in proximity to conspeciﬁc by the WT test ﬁsh. (E) Isotocin and (F)
dOTK2−C8 (4b) were injected i.m. immediately prior to acclimatiza-
tion. Values are represented as the means ± SEM of at least 10 animals
in each group. *P < 0.05; ***P < 0.001 versus the corresponding
vehicle group. $$ P < 0.005 versus the 0.05 ng of dose in mice; ### P
< 0.001 and ## P < 0.05 versus the 0.2 ng/kg dose in zebraﬁsh (one-
way ANOVA followed by Bonferroni’s posthoc test); ns, not
signiﬁcant; nd, not determined.
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colorimetric protein assay (DC protein assay, Biorad, Milan, Italy). For
TMH peptide treatment, transfected cells were incubated with 1 μM
TMH peptides for 2 h at room temperature before BRET assays. Cells
were then distributed (80 μg of proteins per well) in a 96-well
microplate (Optiplate, PerkinElmer, Milan, Italy) and incubated in the
presence of various ligand concentrations or vehicle (PBS) for 2 min
prior to the addition of the BRET2 substrate, coelenterazine 400A, also
called Deep Blue C (Biotium, Hayward, CA). Immediately after the
addition of coelenterazine 400A (5 μM), Rluc and GFP10/GFP2
emissions were recorded using a multidetector plate reader Inﬁnite
F500 (Tecan, Milan, Italy) that allows the sequential integration of
light signals detected with two ﬁlter settings (Rluc ﬁlter, 370−450 nm;
and GFP10/GFP2 ﬁlter, 510−540 nm). Data were collected and the
BRET2 signal determined as the ratio of the light emitted by acceptors
(GFP10/GFP2) over donors (Rluc8). The “ligand promoted BRET”
value was calculated by subtracting the BRET signal measured with
ligand from the one obtained in the vehicle condition as in ref 34. In
BRET saturation experiments, constant amounts of wild type or
mutant C47A or V43A/C47A OTR-Rluc plasmid (0.5 μg) were
cotransfected in HEK293 cells with increasing amounts of the
corresponding OTR-GFP2 plasmids (0−1.5 μg in 35 mm/well).
CD4-GFP2 was used as a negative control of dimerization. The
expression level of each tagged receptor was determined by direct
measurement of total ﬂuorescence and luminescence in an aliquot of
the transfected cells. Total ﬂuorescence was measured using a TECAN
Inﬁnite F500 microplate reader with an excitation ﬁlter at 340 ± 25
nm and an emission ﬁlter at 535 ± 25 nm for GFP2/GFP10. After
ﬂuorescence measurement, the same cell sample was incubated for 8
min with 5 μM coelenterazine h (Biotium, Hayward, CA, USA), and
the total luminescence was measured (from 370 to 450 nm) using a
TECAN Inﬁnite F500 microplate reader. BRET signals were calculated
immediately after the adjunction of coelenterazine 400A (5 μM,
Biotium) using the Rluc ﬁlter, 370−450 nm, and GFP2 ﬁlter, 510−540
nm, and were calculated as the ratio of the emission of GFP2 over the
emission of Rluc. BRET saturation data were analyzed using the Graph
Pad Prism 5.0 software by nonlinear regression assuming a one-phase
exponential association.
Ligand Binding Assays. Binding assays were performed at 30 °C
on membranes prepared from COS7 cells as previously described.38
[125I]d(CH2)5[Tyr(Me)
2, Thr4, and Tyr-NH2
9]OVT ([125I]-OVTA)
were purchased from PerkinElmer (Waltham, MA, USA). Compound
aﬃnities were determined by means of competition experiments in
which the unlabeled compound concentrations varied from 10−15 to
10−6 M, and the concentration of the radioligand [125I]-OVTA was
10−11 M. Nonspeciﬁc binding was determined in the presence of
unlabeled OT (10−6 M). All assays were performed in triplicate and
repeated at least thrice.
Homology Modeling and Ligand Docking. Details are
provided in the Supporting Information, Experimental Section. Brieﬂy,
the monomeric OTR active conformation was built mainly on the
basis of the β2-adrenergic crystal structure (PDB ID 3SN6).63
Homodimeric OTR constellations were designed by using the K-
opioid receptor (KOR) (PDB ID 4DJH) and chemokine receptor type
4 (CXCR4) (PDB ID 3ODU) crystal structures as templates for
protomer arrangements and to simulate dimer interfaces TMH1-
TMH2-H8 and TMH5-TMH6-intracellular loop 2 (ICL2), respec-
tively. Monomeric OTR/dOTK (2) complexes were superimposed
with the protomers of KOR and CXCR4 dimers in an inactive
conformation (the only dimer conformations available at present in
the literature).
For binding of the bivalent ligands into the dimeric OTR, we
assumed identical binding modes of dOTK (2) in the putative
orthosteric binding sites of OTR protomers forming the dimer, which
was comparable to the monovalent ligand in a monomeric OTR.
Therefore, in a ﬁrst step, monovalent dOTKs were constrained in their
binding mode at both protomers of the two hypothesized main OTR
dimer constellations (see above) and connected by spacers with
diﬀerent lengths. These complexes were optimized concerning the
spacers’ bond-length and conformation. Initial minimization was
performed by constraining the backbone of the TMHs and the ligand-
backbone atoms. As none of the bivalent spacer lengths were suitable
to bridge the distance between the dOTK moieties in the OTR dimer
with a TMH5-TMH6-ICL2 interface by maintenance of the two
orthosteric ligand binding sites, further molecular dynamic simulations
were conducted only to the dimeric models with the TMH1-TMH2-
helix 8 interface, followed by energy minimization to justify and
energetically optimize the bivalent ligand orientation inside the OTR
dimers.
Site-Directed Mutagenesis. Enzymes for molecular cloning were
purchased from New England Biolabs (Ipswich, MA, USA) and
Promega (Madison, WI, USA). Oligonucleotides were synthesized by
Euroﬁns MWG Operon (Ebersberg, Germany). DNA sequencing was
performed by Euroﬁns MWG Operon (Ebersberg, Germany). DNA
puriﬁcation kits were obtained from Promega. PCR ampliﬁcation was
performed using the GC-rich PCR system (Roche, Monza, Italy). For
cloning purposes, E. coli DH5α bacteria were used (Invitrogen, Life
Technologies, NY, USA).
All mutations were introduced into the hOTR-pRK564 using
standard PCR mutagenesis techniques.65 The oligonucleotidic primers
(reported in the Supporting Information, Experimental Section) were
designed on the basis of the sequence deposited at the NCBI
(accession number NM 000196).
Sociability and Social Preference. Oxtr+/− mice66 were obtained
from L. Young (Emory University, Atlanta, GA, USA) and housed as
reported in the Supporting Information, Experimental Section. Adult
WT zebraﬁsh were obtained by a local aquarium supply store
(Aquarium Center, Milan, Italy). All of the experimental procedures
followed the guidelines established by the Italian Council on Animal
Care and were approved by Italian Government Decree No. 17/2013
for mice and 18/2013 for zebraﬁsh. Every eﬀort was made to minimize
the number of animals used and their suﬀering.
For the sociability test in mice, a rectangular, three-chamber
transparent polycarbonate box was employed, and the test was
conducted as previously described;52 procedural details are reported in
Supporting Information, Experimental Section.
Social preference in zebraﬁsh was carried out in a large glass
aquarium according to a previous study.53 Brieﬂy, a WT zebraﬁsh test
ﬁsh was allowed to recognize two shoal stimuli, a Nacre mutant, and a
WT counterpart, located in two opposite areas of the aquarium for up
to 15 min (further details are described in Supporting Information,
Experimental Section). Shoaling preference was quantiﬁed by
recording the total time spent by the WT test ﬁsh in proximity to
each stimulus shoal.
OT (1) and dOTK2−C8 (4b) were dissolved in cerebrospinal ﬂuid
and administered intracerebroventricularly (i.c.v) to mice via an
implanted cannula (Supporting Information, Experimental Section) in
a total volume of 2 μL/mouse with a dose ranging from 0.005 to 0.5
ng/mouse, 10 min prior to the sociability test. For zebraﬁsh, isotocin
(IT) (Bachem, Bubendorf, Switzerland) and dOTK2−C8 were
dissolved in saline and administered intramuscularly (i.m.) (Support-
ing Information, Experimental Section) immediately prior the start of
the test, with doses ranging between 0.002 and 1 ng/kg. All solutions
were freshly prepared daily from stocks stored at −20 °C.
Data Analysis. Data analysis, statistical signiﬁcance, and curve
ﬁtting were calculated using Graph-Pad Prism software, version 5
(GraphPad Software, Inc., San Diego, CA). To determine the best
ﬁtting, monophasic vs biphasic models were compared for each data
set. Data points are reported as the mean ± SEM. Estimated parameter
values (EC50, Hill coeﬃcient, Emax, Ki) represent the mean ± SE of at
least three independent experiments each performed at least in
triplicate.
BRET data of Gq activation were analyzed with a nonlinear
regression curve ﬁtting procedure. Monophasic curves where analyzed
using the four-parameter logistic model:
= + − + −
*
∧Y EC Xbottom (top bottom)/(1 10 ((log )
Hill slope))
50
where top and bottom represent the lower and upper plateaus,
respectively.
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Biphasic curves were analyzed using a seven parameters model for
nonmonotonic curves67 as modiﬁed in ref 68:
δ = +
−
+ − *
+
−
+ − *
∧
_
∧
_
EC X b
E
EC X b
bottom
plateau bottom
1 10 (log )
plateau
1 10 (log )
1
50 1 1
max 1
50 2 2
where δ = response; X = log concentration of the agonist; bottom =
response when X = 0; EC50−1 and EC50−2 = concentrations of the
agonist that produce half of the response of the ﬁrst and second
component, respectively; b1 and b2 = slopes of the ﬁrst and second
component, respectively; Plateau1 = maximal response of the ﬁrst
component; Emax = response for an inﬁnite concentration of X, with
constrained b1 and b2 equal to −1. Data from radioligand binding were
evaluated by one-site and two-site competitive binding curve-ﬁtting
procedures using GraphPad Prism version 5. Synthetic transmembrane
peptide eﬀects on dimerization were analyzed by means of one-way
ANOVA followed by Dunnett’s posthoc test comparing all columns to
the control (NT) column. Mice and zebraﬁsh behavioral data were
analyzed by means of one-way ANOVA for multiple comparisons
followed by Tukey’s or Bonferroni’s posthoc test. A statistical level of
signiﬁcance of P < 0.05 was accepted.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.jmed-
chem.6b00564.
Supporting ﬁgures, supporting experimental section, and
supporting notes (PDF)
PDB coordinates for docking pose of 2 in the
monomeric OTR (PDB)
PDB coordinates for docking of 4b in the dimeric OTR
(PDB)
PDB coordinates for docking of 4e in the dimeric OTR
(PDB)
SMILES data (CSV)
■ AUTHOR INFORMATION
Corresponding Author
*CNR, Institute of Neuroscience, Via Vanvitelli 32, 20129
Milano, Italy. Phone: +39-02-50316958. Fax: +39-02-
50317132. E-mail: b.chini@in.cnr.it.
Author Contributions
M.B. performed radioligand binding, functional assays, BRET
experiments, FACS analysis and ﬂuorescence microscopy,
generated mutant receptors, performed data analysis, and
wrote the manuscript. G.K. conducted docking and homology
modeling, suggested receptor mutations, and wrote the
manuscript. M.Mu. synthesized dOTK, dOTK2−C6, dOTK2−
C8, dOTK2−C10, dOTK2−C12, and dOTK2−C14 and wrote
the manuscript. S.S. synthesized dOTK, dOTK2−C8, dOTK-
C8, and wrote the corresponding experimental section. L.B.,
L.A.H., and P.J.M. designed and synthesized the disrupting
peptides and edited the manuscript. M.Ma. planned and
supervised dOTK, dOTK2−C8, and dOTK-C8 chemical
synthesis and wrote the corresponding experimental section.
D.B. and M.S. conceived and performed animal behavior assays,
performed data analysis, and wrote the corresponding
experimental section. S.D. generated mutant receptors. G.E.R.
performed data analysis. T.B. performed data analysis and
wrote the manuscript. B.C. conceived and supervised the
project, performed radioligand binding and functional assays,
performed data analysis, and wrote the manuscript.
Notes
The authors declare no competing ﬁnancial interest.
Authors will release the atomic coordinates of presented 3D-
models and experimental data upon article publication. (1)
Oxytocin; (2) dOTK; (3) dOTK-C8; (4a) dOTK2−C6; (4b)
dOTK2−C8; (4c) dOTK2−C10; (4d) dOTK2−C12; and (4e)
dOTK2−C14.
■ ACKNOWLEDGMENTS
This work was supported by the Telethon Foundation (grant
GGP12207), CNR Research Project on Aging and Regione
Lombardia (Project MbMM-convenzione no18099/RCC) to
B.C.; European Union Seventh Framework Program (Marie
Curie grant 254897 and 2013-BP-B-00109), the Secretary of
Universities and Research of the Economy and Knowledge
Department of the Government of Catalonia and ARC DECRA
(DE150100784) to M.Mu.; DFG (grant KL2334/2-2) and
EKFS project 2014_A114 to G.K.; the National Institute of
General Medical Sciences (grant GM-25280) to M.Ma.; and
BBSRC DTP funding to P.J.M. and L.A.H. (MCCORMICK_-
U15DTP1). M.B. is the recipient of a Foundation Umberto
Veronesi postdoctoral fellowship. We thank Dr. C. Galeś,
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